Aeolus Pharmaceuticals(OTC) AOLS

Aeolus Pharmaceuticals, Inc. is a biopharmaceutical firm focused on developing innovative therapeutic compounds. The company addresses critical medical challenges, including biodefense, oncology, and infectious diseases, through a unique class of catalytic antioxidant compounds.

Products and Services

• AEOL 10150 for acute radiation syndrome and chemical exposure
• AEOL 11114B, AEOL 11203, and AEOL 11207 for Parkinson's disease
• AEOL 20415 targeting various infectious diseases

Growth Outlook

• Pipeline includes multiple candidates targeting significant health issues
• Successful Phase I trials for AEOL 10150 enhance market potential
• Focus on biodefense and oncology aligns with growing healthcare needs

Financial Highlights

• Recent quarterly revenue of $13,000, reflecting ongoing development costs
• Cash and short-term investments totaled $403,000 as of June 30, 2017
• Current ratio of 4.25 indicates strong liquidity position

Aeolus Pharmaceuticals, Inc. operates within the Drug Manufacturers - Specialty & Generic industry and is headquartered in Mission Viejo, California. The company has a focused approach to developing therapies that address urgent medical needs, particularly in the context of biodefense and chronic diseases. The flagship product, AEOL 10150, has shown promise in clinical trials, positioning the company for potential growth in the biopharmaceutical sector. Despite recent financial challenges, the liquidity ratios suggest a capacity to navigate ongoing research and development efforts. The strategic focus on innovative treatments may attract interest from investors looking for opportunities in the healthcare market.